Figure 1 Milestones in coronary angioplasty

Slides:

Advertisements

Similar presentations

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.

Advertisements

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Nat. Rev. Cardiol. doi: /nrcardio

DRug Eluting Bbsorbable Metal Scaffold (DREAMS)

The MASS-DAC Study.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Nat. Rev. Cardiol. doi: /nrcardio

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Catheter-Based Treatment of Coronary Artery Disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Precision prescribing

Figure 1 Anatomy of the femoral artery

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Nat. Rev. Cardiol. doi: /nrcardio

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Figure 4 Cardiology is replete with examples of fractal structures

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

Nat. Rev. Cardiol. doi: /nrcardio

Ana Rita Ramalho et al. JCIN 2017;10:

Figure 1 Manual thrombus aspiration

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Observational studies on multiple treatment strategies

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Tornado diagram of one-way deterministic sensitivity analysis.

Figure 1 Ischaemic conditioning

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

P. Michael Grossman et al. JCIN 2009;2:

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Comparison of the change in index of microcirculatory resistance (IMR) at each stage of the primary percutaneous coronary intervention (PPCI) for balloon.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Percentage of percutaneous coronary interventions using drug-eluting stents in a National Health Service setting in England—National Institute for Health.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Figure 1 Milestones in coronary angioplasty Figure 1 | Milestones in coronary angioplasty. The evolution of percutaneous coronary intervention (PCI) is reported as a timeline. The key steps include the first balloon angioplasty performed on patients by Andeas Grüntzig, the introduction into clinical practice of drug-eluting stents to prevent restenosis, and the development of bioresorbable stents, which can be defined as the 'third revolution' of interventional cardiology. Indolfi, C. et al. (2016) Bioresorbable vascular scaffolds — basic concepts and clinical outcome Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.151